Chronic Hand Eczema Treatment Market Size in the 7MM is projected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight's "Chronic Hand Eczema Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Chronic Hand Eczema, historical and forecasted epidemiology as well as the Chronic Hand Eczema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Chronic Hand Eczema market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Hand Eczema pipeline products will significantly revolutionize the Chronic Hand Eczema market dynamics.

To Know in detail about the Chronic Hand Eczema market outlook, drug uptake, treatment scenario and epidemiology trends @ https://www.delveinsight.com/sample-request/chronic-hand-eczema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from Chronic Hand Eczema Market Report
• As per DelveInsight's analysis, in 2023, the total prevalent cases of chronic hand eczema in the 7 MM accounted for approximately 4 million, out of which the US accounted for nearly 2 million cases. These cases are expected to increase during the forecast period owing to the increased exposure to potential triggers for hand eczema, such as frequent handwashing, and the use of harsh chemicals in household cleaners and personal care products.
• Among EU4 and the UK, Germany accounted for the highest prevalent cases of chronic hand eczema i.e. nearly 493 thousand cases followed by France and the UK accounting for approximately 321 thousand and 317 thousand cases respectively.
• There were nearly 1 million diagnosed cases of chronic hand eczema in the US. These cases are expected to increase by 2034 due to environmental factors such as weather conditions, and lifestyle factors such as stress and poor skincare habits.
• Females are affected more than males by chronic hand eczema due to irritants from household and skincare products. In 2023, there were approximately 1 million females and 993 thousand males with chronic hand eczema, in the US.
• In the UK in 2023, there were nearly 52 thousand, 98 thousand, 29 thousand, and 26 thousand cases chronic hand eczema belonging to the age group 20-29 years, 30-49 years, 50-69 years, 70 and above respectively.
• Assessments as per DelveInsight's analysis show that a maximum number of cases belong to moderate chronic hand eczema. In the UK there were a total of approximately 30 thousand prevalent cases of moderate chronic hand eczema in 2023, followed by nearly 21 thousand and 15 thousand mild and severe cases respectively.
• In 2023, Japan represented almost 15% of all chronic hand eczema cases globally. Among the different subgroups, irritant contact eczema had the highest prevalence at around 27%, whereas fingertip eczema had the lowest, accounting for approximately 4% of the cases. These cases are expected to increase by 2034 driven by the modern lifestyles that lead to high stress levels, poor dietary habits, and sedentary behavior exacerbating inflammatory conditions like eczema in Japan.
• The leading Chronic Hand Eczema Companies such as Basilea Pharmaceutica/ Stiefel Laboratories, LEO Pharma, Asana Biosciences and Incyte Corporation, and others
• Promising Chronic Hand Eczema Therapies: TOCTINO (alitretinoin), Delgocitinib, Ruxolitinib, ASN002, and others.

Get a Free sample for the Chronic Hand Eczema Market Report @ https://www.delveinsight.com/sample-request/chronic-hand-eczema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Hand Eczema Overview
Chronic Hand Eczema (CHE) is a persistent inflammatory skin condition affecting the hands, characterized by redness, scaling, itching, cracking, blistering, and pain. It is a common condition, particularly among individuals exposed to irritants and allergens, such as healthcare workers, cleaners, hairdressers, and construction workers. Genetic predisposition, impaired skin barrier function, immune system dysregulation, and environmental triggers contribute to its development. The condition is classified into different subtypes, including irritant contact dermatitis, allergic contact dermatitis, atopic hand eczema, and hyperkeratotic eczema. Symptoms often worsen with frequent handwashing, chemical exposure, temperature changes, and mechanical friction. Chronic Hand Eczema can severely impact quality of life, leading to functional impairment, sleep disturbances, and psychological distress. Chronic Hand Eczema Diagnosis is typically clinical, based on symptoms and history, but may involve patch testing, skin biopsies, or IgE level assessments to identify underlying triggers. Treatment focuses on avoiding irritants, using emollients, topical corticosteroids, calcineurin inhibitors, and barrier creams. In severe cases, systemic immunosuppressants, biologics (such as IL-4/IL-13 inhibitors), JAK inhibitors, and phototherapy may be required. Early intervention, long-term skin care, and emerging targeted therapies are key to improving outcomes and preventing relapses in patients with Chronic Hand Eczema.

Chronic Hand Eczema Epidemiology Segmentation in the 7MM
• Total Prevalence of Chronic Hand Eczema
• Prevalent Cases of Chronic Hand Eczema by severity
• Gender-specific Prevalence of Chronic Hand Eczema
• Diagnosed Cases of Episodic and Chronic Chronic Hand Eczema

Download the report to understand which factors are driving Chronic Hand Eczema epidemiology trends @ https://www.delveinsight.com/sample-request/chronic-hand-eczema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Hand Eczema Marketed Drugs
• TOCTINO (alitretinoin): Basilea Pharmaceutica/ Stiefel Laboratories
TOCTINO (alitretinoin) is an endogenous metabolite of vitamin A. Alitretinoin belongs to the chemical class of retinoids among which isotretinoin (13-cis-retinoic acid) derivative. Retinoids are typically used to treat skin disorders. It is indicated for use in adults who have severe chronic hand eczema that is unresponsive to treatment with potent topical corticosteroids. Patients in whom eczema has predominantly hyperkeratotic features are more likely to respond to treatment than those in whom eczema predominantly presents as pompholyx. Alitretinoin is an investigational product in the US and an approved product in multiple European countries, Canada, and Israel for the treatment of severe chronic hand eczema, refractory to treatment with a potent topical corticosteroid. It has not been approved for use in the US as well as in Japan.

Chronic Hand Eczema Emerging Drugs
• Delgocitinib: LEO Pharma/Japan Tobacco
Delgocitinib (LP0133) is a topical ATP-competitive Janus kinase (pan-JAK) inhibitor for the treatment of inflammatory skin diseases and is intended to offer an improved safety profile compared to topical steroids. Delgocitinib blocks various cytokine signaling pathways and widely suppresses the activation of immune and inflammatory cells, such as T cells, B cells, mast cells, and monocytes which release inflammatory cytokines, such as IL-4, IL-16, and IFN-γ. It improves autoimmune and allergic diseases by inhibiting the action of JAKs, which play key roles in immune activation signaling in cells, by suppressing the over-activation of immune responses. It also promotes keratinocyte production of filaggrin in the skin barrier. Currently, the company is at the filling stage of drug development.

• ARQ-252: Arcutis Biotherapeutics
ARQ-252 is a topical janus kinase 1 (JAK1) inhibitor that has promise as a novel treatment for inflammatory dermatologic diseases, including chronic hand eczema and vitiligo. Many inflammatory cytokines and other signaling molecules rely on the JAK pathway, specifically JAK1, which plays a central role in immune system function. Inhibition of JAK1 has been shown to treat a range of inflammatory diseases, including rheumatoid arthritis, psoriasis, Crohn's disease, and atopic dermatitis. ARQ-252 is differentiated from other topical JAK inhibitors by its high potency and unique selectivity against JAK1 compared to JAK2. ARQ-252's selectivity for JAK1 may confer important safety advantages compared to other topical JAK inhibitors. Currently, the drug candidate is being investigated in a preclinical stage for treating chronic hand eczema and vitiligo.

• ASN002: Asana BioSciences
ASN002 (Gusacitinib) is a potent dual inhibitor of JAK and SYK kinases, which are involved in both cytokine production and signaling. ASN002 inhibits JAK-mediated cytokine signaling and JAK-SYK mediated T- and B-cell proliferation and function. Gusacitinib was granted FDA Fast-Track Designation for moderate-to-severe chronic hand eczema. The drug candidate has completed Phase II clinical evaluation in moderate-to-severe chronic hand eczema patients.

Chronic Hand Eczema Therapies and Key Companies
• TOCTINO (alitretinoin): Basilea Pharmaceutica/ Stiefel Laboratories
• Delgocitinib: LEO Pharma/Japan Tobacco
• ARQ-252: Arcutis Biotherapeutics
• ASN002: Asana BioScience
• Ruxolitinib: Incyte Corporation

To know more about Chronic Hand Eczema treatment, visit @ Chronic Hand Eczema Medications and Companies- https://www.delveinsight.com/sample-request/chronic-hand-eczema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Hand Eczema Drugs Market Insights
Various drug classes are commonly utilized in treating chronic hand eczema. Topical corticosteroids serve as the primary treatment due to their anti-inflammatory properties, effectively alleviating itching, redness, and swelling associated with eczema flare-ups. However, their prolonged usage can result in skin thinning and other adverse effects, necessitating short-term prescriptions or combination therapies. Another class, topical calcineurin inhibitors like tacrolimus and pimecrolimus, suppress the skin's immune response, proving beneficial for sensitive areas like the face and hands. Emollients and moisturizers play a vital role in managing chronic hand eczema by repairing the skin barrier, reducing water loss, and soothing dry, irritated skin. Often, they are combined with other treatments to uphold skin hydration and deter flare-ups. Additionally, topical immunomodulators such as crisaborole modulate the skin's immune response, diminishing inflammation and eczema symptoms. They are typically employed when corticosteroids or calcineurin inhibitors prove ineffective or intolerable.

Chronic Hand Eczema Market Outlook
The current treatment options for chronic hand eczema primarily include topical therapies such as corticosteroids, calcineurin inhibitors, and emollients/moisturizers. These treatments focus on alleviating symptoms, reducing inflammation, and restoring the skin barrier. In severe cases, systemic therapies like oral medications or biologics may be considered. The treatment market for chronic hand eczema is dynamic and driven by various factors, including advancements in medical understanding, emerging therapies, evolving patient preferences, increasing awareness about eczema management among healthcare professionals and patients, and environmental and lifestyle factors.

Discover more about therapies set to grab major Chronic Hand Eczema market share @ Chronic Hand Eczema Clinical Trials and Treatment Landscape- https://www.delveinsight.com/sample-request/chronic-hand-eczema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Hand Eczema Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Chronic Hand Eczema Companies: Basilea Pharmaceutica, Stiefel Laboratories, LEO Pharma, Incyte Corporation, Asana BioSciences, and others
• Chronic Hand Eczema Therapies: TOCTINO (alitretinoin), Delgocitinib, Ruxolitinib, ASN002, and others
• Chronic Hand Eczema Therapeutic Assessment: Chronic Hand Eczema current marketed and Chronic Hand Eczema emerging therapies
• Chronic Hand Eczema Market Dynamics: Chronic Hand Eczema market drivers and Chronic Hand Eczema market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Hand Eczema Unmet Needs, KOL's views, Analyst's views, Chronic Hand Eczema Market Access and Reimbursement

Table of Contents
1. Chronic Hand Eczema Market Report Introduction
2. Executive Summary for Chronic Hand Eczema
3. SWOT analysis of Chronic Hand Eczema
4. Chronic Hand Eczema Patient Share (%) Overview at a Glance
5. Chronic Hand Eczema Market Overview at a Glance
6. Chronic Hand Eczema Disease Background and Overview
7. Chronic Hand Eczema Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Hand Eczema
9. Chronic Hand Eczema Current Treatment and Medical Practices
10. Chronic Hand Eczema Unmet Needs
11. Chronic Hand Eczema Emerging Therapies
12. Chronic Hand Eczema Market Outlook
13. Country-Wise Chronic Hand Eczema Market Analysis (2020-2034)
14. Chronic Hand Eczema Market Access and Reimbursement of Therapies
15. Chronic Hand Eczema Market Drivers
16. Chronic Hand Eczema Market Barriers
17. Chronic Hand Eczema Appendix
18. Chronic Hand Eczema Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.